Home/Pipeline/O2-16 Series

O2-16 Series

HIV

PreclinicalActive

Key Facts

Indication

HIV

Phase

Preclinical

Status

Active

Company

OyaGen

About OyaGen

OyaGen is a privately held, preclinical-stage biotechnology company founded in 2003 with a dual focus on proprietary drug discovery and contract research services. Its core pipeline targets viral infections, including HIV, Ebola, and coronaviruses, with a platform aimed at disabling key viral proteins. The company operates from a state-of-the-art lab in the Rochester BioVenture Center and is seeking significant capital to advance its lead HIV candidate into clinical trials while exploring strategic partnerships or M&A.

View full company profile

Therapeutic Areas

Infectious Diseases Oncology

Other HIV Drugs

Drug	Company	Phase	Status
Vaxine HIV Vaccine	Vaxine	Preclinical	Active
OraQuick® HIV Self-Test	OraSure	Commercial	FDA Approved; Marketed
Tenofovir Disoproxil Fumarate	Hetero	Commercial	Active
NanoDDI	Continuity Biosciences	Pre-clinical	Active
HIV Gene Therapy	Nanite	Pre-clinical	Active
RGFields for HIV	Anapole Technologies	Clinical (phase unspecified)	Active
HIV mAb Program	Adnexus	Pre-clinical	Active
Undisclosed Program	EnnoDC	Phase 1	Active
SBX 2048	Stramsen Biotech	Early-stage Clinical	Active
ALF Platform	Senzo	Pre-clinical	Active
Gilead HIV Franchise	Royalty Pharma	Marketed	Active
ANKTIVA-based regimens	ImmunityBio	Phase 1/2	Active